The U.S. Food and Drug Administration today announced that it is updating the warning labels required on three gadolinium-based MRI contrast agents sold in the U.S. due to the risk of nephrogenic systemic fibrosis.
FDA updates warning labels on gadolinium contrast
Sep 8, 2010
Latest in MRI
Metrasens launches new MRI threat detection system
November 30, 2025
How are imaging modalities portrayed in movies?
November 24, 2025
ConcertAI launches new reimbursement tool
November 21, 2025



.fFmgij6Hin.png?auto=compress%2Cformat&fit=crop&h=100&q=70&w=100)

.fFmgij6Hin.png?auto=compress%2Cformat&fit=crop&h=167&q=70&w=250)











